CyVerse has really nice data repository Discovery Environment. You can upload your data and use it further, however I can't tell you how because I was not successful with that.
Mentioned repository is also great for data sharing, people upload there raw data from experiments, some are public and some can be shared with you. As of analysis, there were Atmosphere, where you could run linux image and use your data. Now it is being reorganized, so you can check it.
As of data security, I believe it is good.
-
Working through CyVerse
Hi, I came across a review article on transcriptomic analysis suggesting that the post-sequencing analysis can be done through CyVerse (or initially known as iPlant Collaborative) as it has a robust infrastructure that includes a data storage facility, cloud infrastructure on remote servers, educational resources, and expertise and etc. I wonder if anybody who has used this can share the pros and cons of using this platform. I don't want my data to be corrupted
. Thank you, really appreciate for any responses!
-
At the intersection of cytogenetics and genomics lies the exciting field of cytogenomics. It focuses on studying chromosomes at a molecular scale, involving techniques that analyze either the whole genome or particular DNA sequences to examine variations in structure and behavior at the chromosomal or subchromosomal level. By integrating cytogenetic techniques with genomic analysis, researchers can effectively investigate chromosomal abnormalities related to diseases, particularly...09-26-2023, 06:26 AM -
Cancer research has been transformed through numerous molecular techniques, with RNA sequencing (RNA-seq) playing a crucial role in understanding the complexity of the disease. Maša Ivin, Ph.D., Scientific Writer at Lexogen, and Yvonne Goepel Ph.D., Product Manager at Lexogen, remarked that “The high-throughput nature of RNA-seq allows for rapid profiling and deep exploration of the transcriptome.” They emphasized its indispensable role in cancer research, aiding in biomarker...09-07-2023, 11:15 PM
Leave a comment: